Tags:Sotigalimab 代理商,Sotigalimab 价格,Sotigalimab 供应商, Sotigalimab supplier,Sotigalimab purchase,Sotigalimab 购买,Sotigalimab 销售
Description
The FDA has granted an orphan drug designation to sotigalimab (APX005M) as a potential therapeutic option for patients with soft tissue sarcoma, according to announcement from Apexigen Inc., the drug developer. A novel, humanized monoclonal antibody, sotigalimab was designed stimulate antitumor immune response and to target CD40, which is a key co-stimulatory receptor that serves to activate innate and adaptive immune systems. When sotigalimab binds to CD40 on antigen-presenting cells, it induces a multifaceted immune response that brings several components of the immune system together to attack the cancer.
Catalog No.
DHD68911
Host species
Humanized
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
2.54 mg/ml
Purity
>95%
Clonality
Monoclonal
Isotype
IgG1-Kappa
Applications
Research Grade Biosimilar
Target
Tumor necrosis factor receptor superfamily member 5, B-cell surface antigen CD40, Bp50, CD40L receptor, TNFRSF5, CDw40, CD40
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P25942
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
APX005M, APX-005, APX-005-M, APX-005M, CAS: 2305607-45-6
Note
For research use only. Not suitable for clinical or therapeutic use.
关键字: Sotigalimab;2305607-45-6;Bp50;CDw40;
武汉佰乐博生物(Biolab Reagents )作为普健生物旗下控股子品牌,专注于引进、整合全球业内高品质蛋白、抗体产品。作为法国ProteoGenix、Antibodysystem品牌亚洲区独家运营代理商。提供近2万种以蛋白、抗体为核心的生命科学试剂,旨在为生命科学科研工作者提供专业、全面、可靠的试剂产品。